These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8595479)

  • 1. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin J; Mazetti P; Mazoyer B; Rivaud S; Ben Ayed S; Malapani C; Pillon B; Agid Y
    Brain; 1995 Dec; 118 ( Pt 6)():1485-95. PubMed ID: 8595479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease.
    Blin J; Ivanoiu A; De Volder A; Michel C; Bol A; Verellen C; Seron X; Duprez T; Laterre EC
    Psychopharmacology (Berl); 1998 Apr; 136(3):256-63. PubMed ID: 9566811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients.
    Blin J; Ivanoiu A; Coppens A; De Volder A; Labar D; Michel C; Laterre EC
    Neuroimage; 1997 Nov; 6(4):335-43. PubMed ID: 9417975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
    Atack JR; Litvan I; Thal LJ; May C; Rapoport SI; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):832-5. PubMed ID: 1955905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical control of vertical and horizontal saccades in progressive supranuclear palsy: An exploratory fMRI study.
    Lemos J; Pereira D; Almendra L; Rebelo D; Patrício M; Castelhano J; Cunha G; Januário C; Cunha L; Freire A; Castelo-Branco M
    J Neurol Sci; 2017 Feb; 373():157-166. PubMed ID: 28131178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy.
    Otsuka M; Ichiya Y; Kuwabara Y; Miyake Y; Tahara T; Masuda K; Hosokawa S; Goto I; Kato M; Ichimiya A
    Ann Nucl Med; 1989 Nov; 3(3):111-8. PubMed ID: 2641456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: an FDG-PET study.
    Amtage F; Maurer C; Hellwig S; Tüscher O; Kreft A; Weiller C; Rijntjes M; Winkler C; Meyer PT
    Parkinsonism Relat Disord; 2014 Aug; 20(8):898-906. PubMed ID: 24935235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on the cerebral glucose metabolism in progressive supranuclear palsy].
    Ma AJ; Guo XJ; Li DC; Zhang BS; Pan XD
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):885-8. PubMed ID: 23291028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idazoxan treatment in progressive supranuclear palsy.
    Ghika J; Tennis M; Hoffman E; Schoenfeld D; Growdon J
    Neurology; 1991 Jul; 41(7):986-91. PubMed ID: 1676832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.
    Asahina M; Suhara T; Shinotoh H; Inoue O; Suzuki K; Hattori T
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):155-63. PubMed ID: 9703164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities.
    Foster NL; Gilman S; Berent S; Sima AA; D'Amato C; Koeppe RA; Hicks SP
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):707-13. PubMed ID: 1527543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cerebral blood flow and oxygen metabolism in patients with pure akinesia and progressive supranuclear palsy].
    Kondo S; Tanaka M; Sun X; Okamoto K; Hirai S
    Rinsho Shinkeigaku; 1994 Jun; 34(6):531-7. PubMed ID: 7955710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.